Bolt Biotherapeutics, Inc. 8-K

What Happened
Bolt Biotherapeutics, Inc. announced the results of its 2026 annual meeting of stockholders held on June 10, 2026. A total of 1,921,567 shares were entitled to vote as of the April 22, 2026 record date, and 877,358 shares were represented in person or by proxy. Two Class II director nominees were elected to serve through the 2029 annual meeting, and PricewaterhouseCoopers LLP was ratified as the company’s independent registered public accounting firm for 2026.

Key Details

• Meeting date and record date: June 10, 2026 (meeting); April 22, 2026 (record date).
• Director election votes:
  • William P. Quinn: 349,358 votes FOR; 52,117 WITHHELD; 475,883 broker non-votes.
  • Jakob Dupont, M.D.: 377,163 votes FOR; 24,312 WITHHELD; 475,883 broker non-votes.
• Auditor ratification vote (PricewaterhouseCoopers LLP): 768,336 FOR; 107,471 AGAINST; 1,551 ABSTAINING.
• Proxies were solicited under Section 14(a) of the Exchange Act. The filing was signed by William P. Quinn (President, CEO & CFO).

Why It Matters
These results confirm board continuity (two Class II directors elected through 2029) and formalize the company’s auditor choice for 2026, both of which are governance items investors watch for oversight and reporting continuity. The sizable broker non-vote count (475,883) indicates many shares were present but not voted on the director elections, which can affect vote dynamics on routine vs. non-routine matters.